Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Transplants due to hepatitis C have declined dramatically thanks to effective treatment.
Those with fatty liver disease and cirrhosis should undergo regular screening.
Tecentriq plus Avastin improved improved overall survival and patient experiences during treatment.
The LIVER Act would increase funding for liver cancer and hepatitis B research and prevention.
Curing hep C slashes risk of death for those with liver cancer history
Smoking cessation, a healthy diet, exercise and weight loss could dramatically reduce new liver cancer cases and liver disease deaths.
Sustained response to direct-acting antivirals prolonged survival by a year and a half.
People treated with Viread, Vemlidy or Baraclude are less likely to develop this malignancy.
Opdivo plus Yervoy led to higher response rates and longer survival than Opdivo alone.
A new study shows that people with the liver disease have substantial financial burden that can impact their care.
Researchers analyzed cancer outcomes among a large group of South Koreans with hepatitis B virus.
Immunotherapy did not improve overall survival but led to fewer side effects and better quality of life.
Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.
Study in China sees an association with several cancer types, especially gastrointestinal malignancies.
Learning to live well with liver disease, even at it’s worst stages, is possible if you know how to.
Keytruda showed modest benefits for people with hepatocellular carcinoma, and combining Opdivo with Yervoy improved outcomes.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.